论文部分内容阅读
目的:探究糖尿病神经病变患者采用依帕斯他联合舒血宁治疗的效果和特点。方法:从我院2012年3月至2014年5月接收并治疗的糖尿病神经病变患者中随机性抽取80例进行回顾性探究和分析,并随机分为对照组和研究组各40例。对照组患者采用的是依帕斯他治疗,研究组在对照组的基础上加用舒血宁治疗,对比两组不同方法治疗后的临床效果。结果:依帕斯他联合舒血宁治疗糖尿病神经病变患者的有效率93%明显优于对照组采用依帕斯他治疗的有效率81%(P<0.05),且研究组患者治疗后腓感觉神经、正中感觉神经、腓运动神经和正中运动神经的传导速度为49.92±2.36、50.41±3.33、49.25±2.14和67.66±3.18 m/s,比对照组治疗后42.28±2.26、40.25±3.19、43.33±3.22和56.08±3.06 m/s明显提高(P<0.05)。两组患者的不良反应发生率没有明显性变化(P>0.05)。结论:针对糖尿病神经病变患者的治疗采用依帕斯他联合舒血宁治疗,不但可以提高神经传导速度、有效的改善患者的神经病变症状,安全性较高,值得在临床上应用。
Objective: To investigate the effect and characteristics of using ipamipast in combination with Shuxuening in patients with diabetic neuropathy. Methods: A total of 80 patients with diabetic neuropathy received and treated in our hospital from March 2012 to May 2014 were retrospectively investigated and analyzed. They were randomly divided into control group and study group (n = 40). Patients in the control group were treated with epalzastat. The study group was treated with Shuxuening on the basis of the control group, and the clinical effects of the two groups were compared after treatment with different methods. Results: The effective rate of 93% in patients with diabetic neuropathy treated with epalxastine and shuxuening was significantly better than that of the control group treated with epalrestat (81%, P <0.05), and the patients in the study group The nerve, median sensory nerve, peroneal motor and median motor nerve conduction velocity of 49.92 ± 2.36,50.41 ± 3.33,49.25 ± 2.14 and 67.66 ± 3.18 m / s than the control group 42.28 ± 2.26,40.25 ± 3.19,43.33 ± 3.22 and 56.08 ± 3.06 m / s significantly increased (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion: The treatment of patients with diabetic neuropathy with Ipastis combined with Shuxuening treatment can not only improve nerve conduction velocity, effectively improve the symptoms of patients with neuropathy, high safety, it is worth clinical application.